Literature DB >> 24486859

Impact of Postoperative Weight Loss on Survival After Resection for Pancreatic Cancer.

Daisuke Hashimoto1, Akira Chikamoto1, Masaki Ohmuraya2, Shinya Abe1, Shigeki Nakagawa1, Toru Beppu1, Hiroshi Takamori3, Masahiko Hirota4, Hideo Baba5.   

Abstract

BACKGROUND: The aim of this study was to assess the effects of postoperative body weight loss on long-term survival after resection for pancreatic cancer.
METHODS: A total of 93 patients with primary pancreatic cancer underwent pancreatic resection between April 2005 and December 2011. Patient characteristics, preoperative body mass index, and changes in postoperative body weight were evaluated retrospectively and correlated with long-term survival.
RESULTS: There was no significant association between survival and preoperative body mass index. Body weight fell by 8.4% at 2 months after surgery and by 9.0% at 4 months after surgery. Severe postoperative body weight losses, both at 2 months (P = .033) and 4 months (P = .014) after surgery, were significantly associated with poor prognosis, especially among patients with stage IA-IIA pancreatic cancer (n = 43) (P = .005 at 2 months and P < .001 at 4 months). Additionally, severe body weight loss tended to be associated with shorter survival among patients with stage IIB-III pancreatic cancer (n = 50), although the difference was not significant. Multivariate analysis revealed that postoperative body weight loss was an independent prognostic factor.
CONCLUSIONS: The results of this study demonstrated that pancreatic cancer patients with severe postoperative body weight loss have poorer postoperative outcomes.
© 2014 American Society for Parenteral and Enteral Nutrition.

Entities:  

Keywords:  body weight; operation; pancreatic cancer; prognosis

Mesh:

Year:  2014        PMID: 24486859     DOI: 10.1177/0148607114520992

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  9 in total

1.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

Review 2.  Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer.

Authors:  Crystal C Lipsey; Adriana Harbuzariu; Danielle Daley-Brown; Ruben R Gonzalez-Perez
Journal:  World J Methodol       Date:  2016-03-26

3.  Impact of celiac neurolysis on survival in patients with pancreatic cancer.

Authors:  Larissa L Fujii-Lau; William R Bamlet; Jason S Eldrige; Suresh T Chari; Ferga C Gleeson; Barham K Abu Dayyeh; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Elizabeth Rajan; Mark D Topazian; Santhi S Vege; Kenneth K Wang; Maurits J Wiersema; Michael J Levy
Journal:  Gastrointest Endosc       Date:  2015-03-20       Impact factor: 9.427

4.  Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy.

Authors:  Andrew E Hendifar; Jonathan I Chang; Brian Z Huang; Richard Tuli; Bechien U Wu
Journal:  J Gastrointest Oncol       Date:  2018-02

Review 5.  Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician.

Authors:  Mohamed O Othman; Diala Harb; Jodie A Barkin
Journal:  Int J Clin Pract       Date:  2018-02-05       Impact factor: 2.503

6.  Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre II): a protocol for a randomized controlled trial.

Authors:  Linda O'Neill; Emer Guinan; Suzanne Doyle; Deirdre Connolly; Jacintha O'Sullivan; Annemarie Bennett; Grainne Sheill; Ricardo Segurado; Peter Knapp; Ciaran Fairman; Charles Normand; Justin Geoghegan; Kevin Conlon; John V Reynolds; Juliette Hussey
Journal:  BMC Cancer       Date:  2020-05-13       Impact factor: 4.430

7.  Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.

Authors:  Daisuke Hashimoto; Sohei Satoi; Hideki Ishikawa; Yasuhiro Kodera; Keiko Kamei; Satoshi Hirano; Tsutomu Fujii; Kenichiro Uemura; Akihiko Tsuchida; Suguru Yamada; Tomohisa Yamamoto; Kiichi Hirota; Mitsugu Sekimoto
Journal:  Trials       Date:  2022-02-12       Impact factor: 2.279

8.  Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.

Authors:  Ningzhen Fu; Kai Qin; Jingfeng Li; Jiabin Jin; Yu Jiang; Xiaxing Deng; Baiyong Shen
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

9.  Russian Consensus on Exo- and Endocrine Pancreatic Insufficiency After Surgical Treatment.

Authors:  Igor E Khatkov; Igor V Maev; Sayyar R Abdulkhalov; Sergey A Alekseenko; Ruslan B Allikhanov; Igor G Bakulin; Natalia V Bakulina; Andrey U Baranovskiy; Ekaterina V Beloborodova; Elena A Belousova; Sergey E Voskanyan; Lyudmila V Vinokurova; Vladimir B Grinevich; Vladimir V Darvin; Elena A Dubtsova; Tatiana G Dyuzheva; Vyacheslav I Egorov; Mikhail G Efanov; Roman E Izrailov; Vyacheslav L Korobka; Bogdan N Kotiv; Nikolay Yu Kokhanenko; Yury A Kucheryavy; Maria A Livzan; Vladimir K Lyadov; Karine A Nikolskaya; Marina F Osipenko; Victor D Pasechnikov; Ekaterina Yu Plotnikova; Oleg A Sablin; Vladimir I Simanenkov; Victor V Tsvirkun; Vladislav V Tsukanov; Alexey V Shabunin; Dmitry S Bordin; Professional Medical Society Pancreatic Club Russia
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.